The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of neoadjuvant chemotherapy (NAC) with accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (aMVAC) in patients (pts) with muscle invasive bladder cancer (MIBC) as a function of age.
 
Matthew R. Zibelman
Honoraria - Pfizer
Consulting or Advisory Role - EMD Serono; Horizon Pharma; Janssen; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Horizon Pharma (Inst); Pfizer (Inst)
Other Relationship - Association of Community Cancer Centers (ACCC)
 
Bianca Lewis
No Relationships to Disclose
 
Eric A. Ross
Patents, Royalties, Other Intellectual Property - Method for Screening Muscle Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy Responsiveness (Inst)
 
Fern Anari
No Relationships to Disclose
 
Pooja Ghatalia
No Relationships to Disclose
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Flatiron Health; Genentech/Roche; Incyte; Janssen; Merck; Pfizer; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)
 
Daniel M. Geynisman
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Pfizer; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Merck (Inst)